Patents by Inventor Nadezhda Aleksandrovna Orlova

Nadezhda Aleksandrovna Orlova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9616103
    Abstract: Provided is a pharmaceutical composition for growth induction in blood vessel tissue which contains purified plasmid DNA encoding a vascular endothelial growth factor (VEGF) and pharmaceutically acceptable excipients that include a cryoprotectant as a vehicle and/or a pH stabilizer for stabilizing the pH in the range of 7.0 to 9.0, in effective quantities. Also provided is a storage method of plasmid DNA which encodes a VEGF comprising mixing the purified plasmid DNA with a solution of at least one cryoprotectant having properties of a vehicle and/or a pH stabilizer in the pH range of 7.0-9.0. The solution is lyophilized and stored at +2 to +8° C. Supercoiled DNA pCMV-VEGF165 may be used which is produced by culturing Esherichia coli strain TOP10/pCMV-VEGF165. The pharmaceutical composition is administered to a human in quantities sufficient to provide a necessary therapeutic effect.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: April 11, 2017
    Assignee: “NEXTGEN” COMPANY LIMITED
    Inventors: Sergej L'vovich Kiselev, Roman Vadimovich Deev, Ivan Ivanovich Vorob'ev, Nadezhda Aleksandrovna Orlova, Artur Aleksandrovich Isaev
  • Publication number: 20150335711
    Abstract: Provided is a pharmaceutical composition for growth induction in blood vessel tissue which contains purified plasmid DNA encoding a vascular endothelial growth factor (VEGF) and pharmaceutically acceptable excipients that include a cryoprotectant as a vehicle and/or a pH stabilizer for stabilizing the pH in the range of 7.0 to 9.0, in effective quantities. Also provided is a storage method of plasmid DNA which encodes a VEGF comprising mixing the purified plasmid DNA with a solution of at least one cryoprotectant having properties of a vehicle and/or a pH stabilizer in the pH range of 7.0-9.0. The solution is lyophilized and stored at +2 to +8° C. Supercoiled DNA pCMV-VEGF165 may be used which is produced by culturing Esherichia coli strain TOP10/pCMV-VEGF165. The pharmaceutical composition is administered to a human in quantities sufficient to provide a necessary therapeutic effect.
    Type: Application
    Filed: August 2, 2013
    Publication date: November 26, 2015
    Applicant: "NEXTGEN" COMPANY LIMITED
    Inventors: Sergej L'vovich Kiselev, Roman Vadimovich Deev, Ivan Ivanovich Vorob'ev, Nadezhda Aleksandrovna Orlova, Artur Aleksandrovich Isaev